PHOENIX, April 20, 2017 /PRNewswire/ -- Paradigm Diagnostics today announced the launch and IRB approval of the Paradigm registry to allow physicians to better collect, share, and visualize data to help advance personalized medicine in oncology.
The Paradigm registry titled "A Prospective Registry Study to Evaluate the Efficacy of Precision Molecular Testing in the Treatment of Advanced Solid Tumors" builds on the discoveries from an independent prospective study performed by the Indiana University School of Medicine. In this study published in 2016, 43% of patients were shown to receive increased progression-free survival from Paradigm's multi-omics approach to guide therapy, compared to 5% of patients that did not receive Paradigm's PCDx-guided therapy. Many of the patients that demonstrated exceptional responses were treated based upon therapeutic associations driven by Paradigm's mRNA and protein expression analysis.
Dr. Janakiraman Subramanian, with St. Luke's Cancer Institute in Kansas City, Missouri, a co-Investigator on the Paradigm registry noted that: "The Paradigm registry allows easy data collection and collaboration supported by informatics tools to provide opportunities for physician-lead research. We look forward to helping expand this project quickly across multiple institutions to advance cancer care."
"Our streamlined information collection and open data model allows for the sharing of molecular results and outcomes with oncology practices that participate," said David Mallery, CEO. "In addition to the known benefits of PCDx for patients, this registry will also help advance physician-led research."
"We're re-imagining how a diagnostic company works," said Dr. Scott Morris, Chief Scientific Officer. "Providing accurate results is not enough. We need to make sure patients live longer and have higher quality of life. We're building the registry to help physicians select the most effective treatments, anticipate toxicity, and get insurance to pay for it. There are apps to predict the best route through traffic, so why can't we predict the best treatment plan for patients? The missing part is outcome data, and the registry will resolve that."
Paradigm is currently working on registry collaborations with large community oncology networks and academic health systems with the goal of leveraging existing infrastructure and clinical trial resources.
Paradigm recently closed a $7M Series B round of financing from Mesa Verde Venture Partners and New Science Ventures to support efforts such as the Paradigm registry.
For more information regarding participation in this project, please email [email protected].
Paradigm Diagnostics offers accurate, comprehensive and clinically actionable cancer genomic profiling and therapeutic information in 4-5 business days to better support patient care. The Paradigm Cancer Diagnostic (PCDx) comprehensive sequencing test analyzes DNA, RNA, and Protein by immunohistochemisty to provide treating physicians and patients with more precise information about the specific cancer pathways in the tumor to allow for more effective decision-making. For more information or to order a test or join the Paradigm registry please visit www.paradigmdx.com, call (602) 850-7000, or email [email protected]. @Paradigm_DX
SOURCE Paradigm Diagnostics